An effective method to reduce the risk of endophthalmitis after intravitreal injection (IVI): Application of 0.25% povidone-iodine

Abdulgani KAYMAZ; Fatih ULAŞ; Adem SOYDAN; Güvenç TOPRAK

doi:https://doi.org/10.28982/josam.901604

Makale detayları

An effective method to reduce the risk of endophthalmitis after intravitreal injection (IVI): Application of 0.25% povidone-iodine

Yazarlar:

Abdulgani KAYMAZ | Fatih ULAŞ | Adem SOYDAN | Güvenç TOPRAK

Yayıncı:

Fatih BAŞAK

Ana Başlıklar:

Cerrahi ve ilgili tıbbi uzmanlıklar

Dergi:

Journal of Surgery and Medicine 2021 Vol.5 Issue 5, pp.421-425

Belge Tipi:

Makale

Yayın Tarihi:

4/2021

Belge Dili:

İngilizce

Document ID (Org No.):

2000498811

Sıklık:

Aylık

eISSN:

2602-2079

DOI:

https://doi.org/10.28982/josam.901604

Özet:

 

Background/Aim: The most important complication after intravitreal injection (IVI) is endophthalmitis, which can result in severe vision loss. This study aims to investigate the effect of 0.25% povidone-iodine (PI) application before IVI on the incidence of endophthalmitis in patients who received intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection.
Methods: A total of 15345 intravitreal anti-VEGF injections and nine endophthalmitis cases after IVI performed at the outpatient injection room of a single university hospital between January 2017 and January 2020 were included in this retrospective cohort study. Before July 2018, after applying 10% PI around the eyes and 5% PI on the eyes, an eyelid speculum was inserted, and the injection was performed. After this date, in addition to these steps, after placing a speculum and determining the injection site with a caliper, 3-4 drops of 0.25% PI were applied just before injection. Topical antibiotics were not used before or after the injection.
Results: Nine cases of endophthalmitis were detected in 3 years. The most common symptoms were vision loss (9/9) and pain in the eye (7/9). All cases had conjunctival hyperemia, cells-hypopyon in the anterior chamber, and cells in the vitreous. The time between injection and re-visiting the clinic due to endophthalmitis symptoms ranged between 2-6 days, and visual acuity varied between hand motion and 0.2. While the number of endophthalmitis cases before July 2018 was 8 (8/8330) in 1.5 years, after the addition of 0.25% PI application to the protocol, only 1 case of endophthalmitis (1/7015) was seen in the last 1.5 years. The rate of endophthalmitis had decreased significantly (P=0.037).
Conclusion: Since July 2018, the addition of 0.25% PI to the standard IVI protocol just before injection has significantly reduced endophthalmitis rates. With this method, endophthalmitis rates may be decreased despite the increasing number of IVIs.

Makale detayları

An effective method to reduce the risk of endophthalmitis after intravitreal injection (IVI): Application of 0.25% povidone-iodine

Yazarlar: Abdulgani KAYMAZ | Fatih ULAŞ | Adem SOYDAN | Güvenç TOPRAK

Yayıncı: Fatih BAŞAK

Ana Başlıklar: Cerrahi ve ilgili tıbbi uzmanlıklar

Dergi: Journal of Surgery and Medicine 2021 Vol.5 Issue 5, pp.421-425

Belge Tipi: Makale

Yayın Tarihi: 4/2021

Belge Dili: İngilizce

Document ID (Org No.): 2000498811

Sıklık: Aylık

eISSN: 2602-2079

DOI: https://doi.org/10.28982/josam.901604

Sayı

Yazarlar:

Abdulgani KAYMAZ | Fatih ULAŞ | Adem SOYDAN | Güvenç TOPRAK

Yayıncı:

Fatih BAŞAK

Ana Başlıklar:

Cerrahi ve ilgili tıbbi uzmanlıklar

Dergi:

Journal of Surgery and Medicine 2021 Vol.5 Issue 5, pp.421-425

Belge Tipi:

Makale

Yayın Tarihi:

4/2021

Belge Dili:

İngilizce

Document ID (Org No.):

2000498811

Sıklık:

Aylık

eISSN:

2602-2079

DOI:

https://doi.org/10.28982/josam.901604